|
| << previous | next >> |
Journal description
All volumes of the corresponding journal
All issues of the corresponding volume
All articles of the corresponding issues
Details for article 3 of 15 found articles
| Title: |
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial |
| Author: |
Soo, R.A. Han, J.-Y. Dafni, U. Cho, B.C. Yeo, C.M. Nadal, E. Carcereny, E. de Castro, J. Sala, M.A. Bernabé, R. Coate, L. Provencio Pulla, M. Garcia Campelo, R. Cuffe, S. Hashemi, S.M.S. Früh, M. Massuti, B. Garcia-Sanchez, J. Dómine, M. Majem, M. Sanchez-Torres, J.-M. Britschgi, C. Pless, M. Dimopoulou, G. Roschitzki-Voser, H. Ruepp, B. Rosell, R. Stahel, R.A. Peters, S. |
| Appeared in: |
Annals of oncology |
| Paging: | Volume 33 () nr. 2 pages 181-192 |
| Year: |
2022 |
| Contents: | |
| Publisher: |
European Society for Medical Oncology |
| Source file: |
Elektronische Wetenschappelijke Tijdschriften |
Details for article 3 of 15 found articles
| << previous | next >> |